Drug Patent List
Oppositions
Newsletter
Weekly Digest

Pharsight

Daridorexant Hydrochloride Patent Expiration

Daridorexant Hydrochloride is Used for treating insomnia. It was first introduced by Idorsia Pharmaceuticals Ltd in its drug Quviviq on Apr 7, 2022.


Daridorexant Hydrochloride Patents

Given below is the list of patents protecting Daridorexant Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Quviviq US10023560 Crystalline salt form of (S)-(2-(6 chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist Dec 02, 2034 Idorsia
Quviviq US9732075 Benzimidazole-proline derivatives Jun 12, 2033 Idorsia
Quviviq US9790208 Crystalline salt form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist Dec 02, 2034 Idorsia


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Daridorexant Hydrochloride's patents.

Given below is the list recent legal activities going on the following patents of Daridorexant Hydrochloride.

Event Date Patent/Publication
Patent litigations
Mail Pub Notice re 312 amendment 31 May, 2024 US9732075
Email Notification 31 May, 2024 US9732075
POST ISSUE OTHER COMMUNICATION TO APPLICANT- CERTIFICATE OF CORRECTION 28 May, 2024 US9732075
Second letter to regulating agency to determine regulatory review period 23 Oct, 2023 US9732075
Letter from FDA or Dept of Agriculture re PTE application 28 Sep, 2023 US9732075
Initial letter Re: PTE Application to regulating agency 28 Dec, 2022 US9732075
Post Issue Communication - Certificate of Correction 18 Nov, 2022 US9732075
Post Issue Communication - Certificate of Correction 01 Aug, 2022 US9732075
Post Issue Communication - Certificate of Correction 20 May, 2022 US9732075
Email Notification 29 Apr, 2022 US9732075



Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳